Great to hear, @Mihai_P .
In answer to your question, essentially tenofovir and entecavir are equivalent in antiviral effect. I’ll refer you to some responses to a similar post:
Hi @lufun ,
There have been controversies over this based on the difference in people treated with either entecavir or tenofovir. Because entecavir was released first, we have more data on it and people who have been on it for longer. People on tenofovir are more likely to be more recently diagnosed. This could lead to a difference in observed HCC rates. My understanding is that once these differences are controlled for, then both entecavir and tenofovir are pretty much equal in preventing liver…
Hi all,
I know of no information that definitively says that tenofovir or entecavir is better at stopping development of liver cancer. They both work the same way, by blocking HBV replication. This reduces hepatic inflammation (a major cancer driver) and also reduces ongoing integration of HBV into the cellular genome (also a cancer driver). Their net antiviral efficacy at the prescribed doses is quite similar, so from a simple mechanistic point of view there is no obvious reason one should …
Cheers,
Thomas
1 Like